FASTER

Frontline T-cell Engager vs Autologous Stem Cell Transplant and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma (FASTER)

Arms / Cohorts

Experimental:Arm B1 (Late Intensification)

Accepting patients

Experimental:Arm A (Elranatamab + Daratumumab)

Accepting patients

Active Comparator:Arm B (ASCT + lenalidomide/daratumumab)

Accepting patients

Experimental:Arm A1 (Late Intensification)

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.